Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07290244 · ClinicalTrials.gov registry record · Phase 1
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
A Phase 1 study of Open Angle Glaucoma (OAG) and NAION( Non-arteritic Anterior Ischemic Optic Neuropathy), sponsored by Life Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 2
- Study locations
NCT07290244: Recruiting Phase 1 study of Open Angle Glaucoma (OAG) and NAION( Non-arteritic Anterior Ischemic Optic Neuropathy), sponsored by Life Biosciences.
NCT07290244 is a Phase 1 study of Open Angle Glaucoma (OAG) and NAION( Non-arteritic Anterior Ischemic Optic Neuropathy) that is actively recruiting participants, run by Life Biosciences. The registered enrollment target is 18 participants, below the 65-participant average among 5 other Open Angle Glaucoma (OAG) trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07290244, a Phase 1 study of Open Angle Glaucoma (OAG) and NAION( Non-arteritic Anterior Ischemic Optic Neuropathy), is actively recruiting participants, sponsored by Life Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). The main questions it aims to answer are: * Is ER-100 safe when given as a single dose to people with OAG or NAION * What side effects may occur, if any, after taking ER-100? Participants will: * Receive a single dose of ER-100 * Undergo safety assessments including detailed eye examination and laboratory tests * Provide body fluid samples (tears, saliva, feces, urine) to help researchers understand how the drug is processed and cleared from the body * Complete questionnaires about their quality of life * Be followed for up to 5 years to monitor long-term health and vision outcomes
Primary Outcome
This outcome tracks any new or worsening health problems that occur while participants are receiving and completed oral doxycycline. These health problems are called treatment-emergent adverse events (TEAEs). Researchers record how often these events happen as well as their nature and seriousness. This helps determine whether ER-100 causes any short-term side effects during this phase.
Conditions Studied
Interventions
- GENETIC ER-100 epigenetic therapy
Study Locations (2)
California
- Global Research Management, Inc. - Glendale
South Carolina
- Charleston Neuroscience Institute - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-03-02 |
| Est. Completion | 2032-03 |
| Phase | Phase 1 |
What NCT07290244 shows while recruiting
NCT07290244 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 65-participant average among 5 other Open Angle Glaucoma (OAG) trials with a reported enrollment target (72% lower).
The record links to 2 conditions, with Open Angle Glaucoma (OAG) appearing as the primary indexed condition, and to 1 intervention - of which ER-100 epigenetic therapy is the first listed.
NCT07290244 reports a single indexed study location in California, South Carolina.
Frequently Asked Questions
What is clinical trial NCT07290244 about?
NCT07290244 is a clinical study titled "Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)". The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). The main questions it aims to answer are: * Is ER-100 saf...
What is the current status of trial NCT07290244?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-03-02. Estimated completion is 2032-03.
What conditions does trial NCT07290244 study?
This clinical trial studies the following conditions: Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy).
What interventions are being tested in trial NCT07290244?
The interventions under investigation include: ER-100 epigenetic therapy (GENETIC).
Who is sponsoring clinical trial NCT07290244?
This trial is sponsored by Life Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07290244 being conducted?
This trial has 2 study locations across California, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Open Angle Glaucoma (OAG)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma
RECRUITING
-
Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
RECRUITING
-
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
RECRUITING · NA
-
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
RECRUITING · Phase 2
-
Travoprost Five Day Posology Study
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI